Plasma copeptin and long-term outcomes in acute ischemic stroke

Acta Neurologica Scandinavica

Volumn 128, Issue 6, 2013, Pages 372-380

  Zhang, J L ^a,b   Yin, C H ^c   Zhang, Y ^b   Zhao, L B ^b   Fu, H J ^b   Feng, J C ^a  

^a JILIN UNIVERSITY   (China)

^b Heilongjiang Province Hospital   (China)

^c MUDANJIANG MEDICAL UNIVERSITY   (China)

Author keywords

1 year outcome; Acute ischemic stroke; Copeptin; Prognostic biomarker

Indexed keywords

BIOCHEMICAL MARKER; COPEPTIN;

ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; CHINESE; CONTROLLED STUDY; FEMALE; FUNCTIONAL STATUS; HORMONE BLOOD LEVEL; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PROGNOSIS; PROSPECTIVE STUDY; SURVIVOR;

1-YEAR OUTCOME; ACUTE ISCHEMIC STROKE; COPEPTIN; PROGNOSTIC BIOMARKER;

AGED; AGED, 80 AND OVER; CHINA; COHORT STUDIES; FEMALE; GLYCOPEPTIDES; HUMANS; IMMUNOASSAY; MALE; MIDDLE AGED; NEUROIMAGING; OUTCOME ASSESSMENT (HEALTH CARE); ROC CURVE; STATISTICS, NONPARAMETRIC; STROKE; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 84886640158     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/ane.12132     Document Type: Article

References (39)

1. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, et al. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008;117:e25-146.
2. Johansson A, Olsson T, Carlberg B, Karlsson K, Fagerlund M. Hypercortisolism after stroke-partly cytokine-mediated? J Neurol Sci 1997;147:43-7.
3. Volpi S, Rabadan-Diehl C, Aguilera G. Vasopressinergic regulation of the hypothalamic pituitary adrenal axis and stress adaptation. Stress 2004;7:75-83.
4. Katan M, Christ-Crain M. The stress hormone copeptin: a new prognostic biomarker in acute illness. Swiss Med Wkly 2010;140:w13101.
5. Katan M, Fluri F, Morgenthaler NG, Schuetz P, Zweifel C, Bingisser R, et al. Copeptin: a novel, independent prognostic marker in patients with ischemic stroke. Ann Neurol 2009;66:799-808.
6. Zhang X, Lu XM, Huang LF, Ye H. Copeptin is associated with one-year mortality and functional outcome in patients with acute spontaneous basal ganglia hemorrhage. Peptides 2012;33:336-41.
7. Zweifel C, Katan M, Schuetz P, Siegemund M, Morgenthaler NG, Merlo A, et al. Copeptin is associated with mortality and outcome in patients with acute intracerebral hemorrhage. BMC Neurol 2010;26:34.
8. Dong XQ, Huang M, Yang SB, Yu WH, Zhang ZY. Copeptin is associated with mortality in patients with traumatic brain injury. J Trauma 2011;71:1194-8.
9. Katan M, Nigro N, Fluri F, Schuetz P, Morgenthaler NG, Jax F, et al. Stress hormones predict cerebrovascular re-events after transient ischemic attacks. Neurology 2011;76:563-6.
10. Hatano S. Experience from a multicentre stroke register: a preliminary report. Bull World Health Organ 1976;54:541-53.
11. Adams HP Jr, Bendixen BH, Kappelle LJ et al. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial. TOAST: trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24:35-41.
12. Bonita RBR. Modification of Rankin Scale: recovery of motor function after stroke. Stroke 1988;19:1497-500.
13. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem, 2006;52:112-19.
14. Whiteley W, Chong WL, Sengupta A, Sandercock P. Blood markers for the prognosis of ischemic stroke: a systematic review. Stroke 2009;40:e380-9.
15. di Napoli M, Papa F, Bocola V. Prognostic influence of increased C-reactive protein and fbrinogen levels in ischemic stroke. Stroke 2001;32:133-8.
16. Elkind MS, Tai W, Coates K, Paik MC, Sacco RL. High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. Arch Intern Med 2006;166:2073-80.
17. Shantikumar S, Grant PJ, Catto AJ, Bamford JM, Carter AM. Elevated C-reactive protein and long-term mortality after ischaemic stroke: relationship with markers of endothelial cell and platelet activation. Stroke 2009;40:977-9.
18. Whiteley W, Jackson C, Lewis S, Lowe G, Rumley A, Sandercock P, et al. Inflammatory markers and poor outcome after stroke: a prospective cohort study and systematic review of interleukin-6. PLoS Med 2009;6:e1000145.
19. Kelly PJ, Morrow JD, Ning M, Koroshetz W, Lo EH, Terry E, et al. Oxidative stress and matrix metalloproteinase-9 in acute ischemic stroke. The Biomarker Evaluation for Antioxidant Therapies in Stroke (BEAT-Stroke) study. Stroke 2008;39:100-4.
20. Del Z, Levy DE, Wasiewski WW, Pancioli AM, Demchuk AM, Trammel J, et al. Hyperfibrinogenemia and functional outcome from acute ischemic stroke. Stroke 2009;40:1687-91.
21. Whiteley W, Rumley A, Sattar N, Wardlaw JM, Lowe GDO, Welsh P, et al. POS11 blood markers and poor outcome after acute cerebrovascular disease: a prospective cohort study. J Neurol Neurosurg Psychiatry 2010;81:e70.
22. Neidert S, Katan M, Schuetz P, Fluri F, Ernst A, Bingisser R, et al. Anterior pituitary-axis hormones and outcome in acute ischemic stroke. J Intern Med 2011;269:420-32.
23. Urwyler SA, Schuetz P, Fluri F, Morgenthaler NG, Zweifel C, Bergmann A, et al. Prognostic value of copeptin: one-year outcome in patients with acute stroke. Stroke 2010;41:1564-7.
24. Nickel CH, Bingisser R, Morgenthaler NG. The role of copeptin as a diagnostic and prognostic biomarker for risk stratification in the emergency department. BMC Med 2012;10:7.
25. Meisel A, Meisel C, Harms H, Hartmann O, Ulm L. Predicting post-stroke infections and outcome with blood-based immune and stress markers. Cerebrovasc Dis 2012;33:580-8.
26. de Marchis GM, Katan M, Weck A et al. Copeptin and risk stratification in patients with ischemic stroke and transient ischemic attack: the CoRisk Study. Int J Stroke 2013;8:214-218.
27. Morgenthaler NG, Muller B, Struck J, Bergmann A, Redl H, Christ-Crain M. Copeptin, a stable peptide of the arginine vasopressin precursor, is elevated in hemorrhagic and septic shock. Shock 2007;28:219-26.
28. Khan SQ, Dhillon OS, O'Brien RJ, Struck J, Quinn PA, Morgenthaler NG, et al. C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: leicester Acute Myocardial Infarction Peptide (LAMP) study. Circulation 2007;115:2103-10.
29. Gegenhuber A, Struck J, Dieplinger B, Poelz W, Pacher R, Morgenthaler NG, et al. Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure. J Card Fail 2007;13:42-9.
30. Shuaib A, Xu W, Yang T, Noor R. Effects of nonpeptide V(1) vasopressin receptor antagonist SR-49059 on infarction volume and recovery of function in a focal embolic stroke model. Stroke 2002;33:3033-7.
31. Oghlakian G, Klapholz M. Vasopressin and vasopressin receptor antagonists in heart failure. Cardiol Rev 2009;17:10-15.
32. Rose CE Jr, Anderson RJ, Carey RM. Antidiuresis and vasopressin release with hypoxemia and hypercapnia in conscious dogs. Am J Physiol 1984;247:R127-34.
33. Jochberger S, Mayr VD, Luckner G, Wenzel V, Ulmer H, Schmid S, et al. Serum vasopressin concentrations in critically ill patients. Crit Care Med 2006;34:293-9.
34. Armstead WM. Vasopressin-induced protein kinase C-dependent superoxide generation contributes to atp-sensitive potassium channel but not calcium-sensitive potassium channel function impairment after brain injury. Stroke 2001;32:1408-14.
35. Vakili A, Kataoka H, Plesnila N. Role of arginine vasopressin V1 and V2 receptors for brain damage after transient focal cerebral ischemia. J Cereb Blood Flow Metab 2005;25:1012-19.
36. Kozniewska E, Gadamski R, Klapczynska K, Wojda R, Rafalowska J. Morphological changes in the brain during experimental hyponatremia. Do vasopressin and gender matter?. Folia Neuropathol 2008;46:165-70.
37. Kozniewska E, Romaniuk K. Vasopressin in vascular regulation and water homeostasis in the brain. J Physiol Pharmacol 2008;59(Suppl 8):109-16.
38. Katan M, Morgenthaler N, Widmer I, Puder JJ, Konig C, Muller B, et al. Copeptin, a stable peptide derived from the vasopressin precursor, correlates with the individual stress level. Neuro Endocrinol Lett 2008;29:341-6.
39. Potocki M, Breidthardt T, Mueller A. Copeptin and risk stratification in patients with acute dyspnea. Crit Care 2010;14:R213.